Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Litoxetine HCl is a selective 5-hydroxytryptamine (5-HT) reuptake inhibitor (SSRI) and mixed 5-hydroxytryptamine antagonist used in the treatment of urinary incontinence. Litoxetine HCl in the absence of antimuscarinic concentrations without antimuscarinic properties (10 nM-1 microM) caused concentration-dependent relaxation of isolated oesophageal muscle mucosa in rats, reducing carbachol tone by up to 37%. Higher concentrations of Litoxetine HCl (3 microM-300 microM) were associated with significant relaxation up to abolition of carbachol tone. The antiarrhythmic activity of Litoxetine HCl, previously demonstrated in the isolated guinea pig intestine, was exerted in the isolated rat oesophageal muscle mucosa at concentrations greater than 1 microM. The 5-HT-releasing effect of Litoxetine HCl could explain the potency of Litoxetine HCl on 5-HT-induced relaxation in untreated rat tissue, which was reversed by pCPA treatment.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 22,500 | |||
5 mg | 在庫あり | ¥ 52,500 | |||
10 mg | 在庫あり | ¥ 79,000 | |||
25 mg | 在庫あり | ¥ 134,500 | |||
50 mg | 在庫あり | ¥ 192,500 | |||
100 mg | 在庫あり | ¥ 266,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 50,500 |
説明 | Litoxetine HCl is a selective 5-hydroxytryptamine (5-HT) reuptake inhibitor (SSRI) and mixed 5-hydroxytryptamine antagonist used in the treatment of urinary incontinence. Litoxetine HCl in the absence of antimuscarinic concentrations without antimuscarinic properties (10 nM-1 microM) caused concentration-dependent relaxation of isolated oesophageal muscle mucosa in rats, reducing carbachol tone by up to 37%. Higher concentrations of Litoxetine HCl (3 microM-300 microM) were associated with significant relaxation up to abolition of carbachol tone. The antiarrhythmic activity of Litoxetine HCl, previously demonstrated in the isolated guinea pig intestine, was exerted in the isolated rat oesophageal muscle mucosa at concentrations greater than 1 microM. The 5-HT-releasing effect of Litoxetine HCl could explain the potency of Litoxetine HCl on 5-HT-induced relaxation in untreated rat tissue, which was reversed by pCPA treatment. |
ターゲット&IC50 | [3H]-DAU 6215:0.3 microM |
In vitro |
Litoxetine HCl (0.3-3 microM) antagonized the high- and low-potency phases of the 5-HT curve.[1] Litoxetine HCl (1 and 3 microM) responses to 5-MeOT were shifted to the right in a concentration-dependent manner.[1] |
In vivo | Litoxetine HCl (twice daily for 4 days), a novel specific serotonin reuptake inhibitor.[2] |
別名 | litoxetine HCL(86811-09-8 Free base) |
分子量 | 277.79 |
分子式 | C16H20ClNO |
CAS No. | T67956L |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22.5 mg/mL (81 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Litoxetine HCl T67956L GPCR/G Protein Neuroscience 5-HT Receptor litoxetine HCL(86811-09-8 Free base) Inhibitor inhibitor inhibit